China to ‘refine’ centralised medicine procurement policies
Sign up now: Get ST's newsletters delivered to your inbox
China’s healthcare regulator in February said the quality concerns were unsubstantiated.
PHOTO: AFP
Follow topic:
SHANGHAI - China will refine its centralised drug procurement policy, said an official report on March 5, after a recent probe into quality concerns over off-patent medicines approved for distribution to public hospitals.
“We will refine the policy for centralised medicine procurement and enhance quality evaluations and oversight to ensure that our people have full confidence in the medication they use,” said the report.
It added that China would also “improve pricing mechanisms”, and create a “medical insurance catalogue” for innovative drugs to “support their development”.
China’s healthcare regulator in February said the quality concerns were unsubstantiated. REUTERS
